{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-23-000434","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.456702+00:00","generated_at":"2026-06-10T14:49:26.127611+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Regen Biopharma enters $175K promissory note and $10M equity line with Coventry","bullets":["Net proceeds $148,750 after $26,250 original issue discount; note matures March 2025.","Note carries 10% interest, convertible upon default at 90% of lowest 20-day trading price.","Equity line allows draw downs at 80% of lowest price over prior 10 business days; max $250K per draw.","Coventry receives 125,000 commitment shares; registration statement to cover up to 1,126,954 shares.","Draw downs limited to 200% of average daily dollar traded value; beneficial ownership cap 4.99%."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-23-000434","json":"https://secwatch.observer/filing/0001607062-23-000434.json","markdown":"https://secwatch.observer/filing/0001607062-23-000434.md","text":"https://secwatch.observer/filing/0001607062-23-000434.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/0001607062-23-000434-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/rgbp091823form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:49:26.127611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2690732783f0998a6e91febfb5d1e61d5304a8a0","claim":"Regen BioPharma Inc entered into Purchase Agreement with Coventry Enterprises, LLC valued at $175,000 (effective 2023-09-12).","evidence_excerpt":"Effective September 12, 2023 Regen Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Coventry Enterprises, LLC (“Coventry”), pursuant to which Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/0001607062-23-000434-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Coventry Enterprises, LLC"},{"label":"Value","value":"$175,000"},{"label":"Effective","value":"2023-09-12"}],"fact_type":"material_agreement"},{"claim_id":"9e8c36308077745e5d244263c96afb30fa173c32","claim":"Regen BioPharma Inc entered into Registration Rights Agreement with Coventry (effective 2023-09-12).","evidence_excerpt":"In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/0001607062-23-000434-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Coventry"},{"label":"Effective","value":"2023-09-12"}],"fact_type":"material_agreement"},{"claim_id":"d5b516b94ab008c8348c86a54c6d50e51607c6c4","claim":"Regen BioPharma Inc entered into common stock purchase agreement with Coventry valued at up to Ten Million Dollars ($10,000,000) (effective 2023-09-12).","evidence_excerpt":"On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry providing for an equity financing facility (the “Equity Line”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1589150/000160706223000434/0001607062-23-000434-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Coventry"},{"label":"Value","value":"up to Ten Million Dollars ($10,000,000)"},{"label":"Effective","value":"2023-09-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}